Provided is a new means for administering a valuable substance having a fat dissolving action. A microneedle preparation including at least one of a lipolytic agent, a fat dissolving agent, or a fat metabolism promoting agent, the microneedle preparation being intended for fat reduction and/or partial slenderizing and/or skin tightening, and a microneedle preparation including a microneedle array containing a water-soluble polymer as a base and one or more selected from the group consisting of a lipase, a phosphatidylcholine, and deoxycholic acid.

The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and live attenuated PRRS virus for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus by administration of the vaccine into the dermis of the animal.

A melt processed viral nanoparticle construct for delivery of virus or virus-like particles to a site of interest includes a degradable polymer matrix and a plurality of virus or virus-like particles encapsulated within the degradable polymer matrix. The nanoparticle construct upon administration to the site of interest providing a sustained release of the virus or virus-like particles and/or nanoparticles upon degradation of the polymer matrix.

Disclosed herein are water-soluble microneedle spicules for scrubs and a non-aqueous cosmetic composition containing the same. More specifically, the present invention relates to water-soluble microneedle spicules for scrubs, which are in the shape of a triangular pyramid or sexangular pyramid and characterized in that at least any one among the interior angles of the pyramid base of the spicules for scrubs is 90 degrees or less; and a non-aqueous cosmetic composition containing the same. 10 110, 120, 130: Separation 14 mixture: Gene Mixture 15 : Test Group : Control Group

A microneedle device of the present invention comprises a substrate, microneedles disposed on the substrate, and a coating layer formed on the microneedles, wherein a length of the microneedles is 300 to 500 μm, the microneedles are disposed on the substrate at a density of 28 to 80 needles/cm.sup.2, and the coating layer comprises a biologically active substance. The microneedle device allows the skin irritation caused by administration of an agent to be reduced.

Provided herein is a topical combination composition comprising tapinarof, an additional AhR activator and optionally further comprising at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions.

The present disclosure provides lyophilates comprising (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate: and pharmaceutical compositions, pharmaceutical formulations, and uses thereof.

##STR00001##

A drug delivery system is described comprising a detachable support and a plurality of drug-loaded transdermal microneedles, for delivering drugs into gingival tissue for the treatment of periodontal disease.

The present invention relates to the synergistic effect of calcium hydroxyapatite particles and hyaluronic acid on the bio-stimulation. The invention refers to an injectable composition comprising one or more types of calcium hydroxyapatite particles and hyaluronic acid and to a method for preparing such injectable composition. Furthermore, it relates to a cosmetic method for improving appearance of the skin and/or contour of a subject by means of the injectable composition. Moreover, the invention refers to the injectable composition for use in a method of treating a pathologic condition associated with pathologic deterioration of connective tissue.

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. Some of the hyaluronic acid-based compositions can include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. Compared to conventional compositions that include lidocaine, some of the hyaluronic acid-based compositions disclosed herein can have an enhanced stability, for example, when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such compositions are also provided.